Premium
PLGA nanoparticles loaded with antitumoral drug as a Drug Delivery System
Author(s) -
Dias Diego Juscelino Santos,
Joanitti Graziella A,
Silva Luciano P,
Lunardi Claure N,
Gomes Anderson J
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.575.8
Subject(s) - zeta potential , bioavailability , plga , chemistry , drug , nanoparticle , drug delivery , cytotoxicity , pharmacology , nuclear chemistry , chlorambucil , pharmacokinetics , in vitro , nanotechnology , materials science , biochemistry , chemotherapy , organic chemistry , medicine , surgery , cyclophosphamide
Chlorambucil (CHB) is an anticancer agent used in conventional treatment of a variety of cancers, particularly in chronic lymphocyte leukemia and autoimmune disease. This use is restricted because undesirable side effects. To overcome this situation CHB was encapsulated in nanoparticles (NPs) of poly(D,L‐lactide‐co‐glycolide) acid (PLGA) using the double emulsion technique. CHB‐NP were evaluated in relation to parameters such as drug encapsulation efficiency using 10 mg CHB (93,10±0,71%), release profile (79% in 24 h), particle size (285,50±46,85 nm), zeta potential (−17,00±0,42 mV) and also physical chemistry properties of CHB‐NP were recorded (FT‐IR and UV‐vis absorptions, emission of fluorescence TGA/DTA and DSC). The spherical morphology of the NPs was analyzed through SEM. Cytotoxicity of CHB‐NP were studied in two different cells line: NIH‐3T3(64.5%) and MCF7 (64.8%) by MTT assay. DDS produced in this work showed to be a promising way to improve bioavailability, to reduce adverse effects and could be more potent agent than free CHB. Financial support: CNPq, CAPES, FAPDF, FINATEC, DPP‐UnB